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Abstract
Objective. To investigate the analgesic efficacy of
electroacupuncture (EA) in patients with chronic
painful neuropathy.
Design. Double-blind, placebo-controlled, cross-
over study. Inclusion criteria were diagnosis of
peripheral neuropathy, neuropathic pain (visual
analog scale > 4) for at least 6 months, and stable
analgesic medications for at least 3 months.
Patients. Sixteen patients were randomized into two
arms to be treated with EA or pseudo-EA (placebo).
Interventions. The protocol included 6 weeks of
treatment, 12 weeks free of treatment, and then
further 6 weeks of treatment. EA or pseudo-EA was
performed weekly during each treatment period.
Outcome Measures. The primary outcome was the
number of patients treated with EA achieving at
least 50% of pain relief at the end of each treatment
compared with pain intensity at baseline. Secon-
dary outcomes were modification in patient’s global
impression of change, depression and anxiety, and
quality of life.
Results. Eleven patients were randomized to EA
and five patients to pseudo-EA as the first treatment.
Only one patient per group (EA and pseudo-EA)
reported 50% of pain relief at the end of each treat-
ment compared with pain intensity at baseline. Pain
intensity did not differ between EA (5.7  2.3 at
baseline and 4.97  3.23 after treatment) and
pseudo-EA (4.9  1.9 at baseline and 4.18  2.69
after treatment). There was no difference between
patients who received EA as the first treatment and
patients initially treated with placebo. There was no
change in the secondary outcomes.
Conclusions. Our results do not support the use of
EA in this population of painful neuropathy patients.
Further studies in larger groups of patients are war-
ranted to confirm our observation.
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Introduction
Neuropathic pain is a relatively common condition occur-
ring in about 4–5% of the population [1]. However, treat-
ment options are limited due to the variable and
unpredictable responses, while optimum dose for any
drug may vary from patient to patient. Recent meta-
analysis reported that current treatments can achieve
30–50% reduction in pain intensity in only 25–50% of
patients [2–4]. Peripheral neuropathies are a frequent
cause of chronic neuropathic pain that can severely affect
patients’ quality of life [5–8] and increase the socioeco-
nomic costs [9]. Etiological therapies are available only in
few specific conditions, such as in patients with neuro-
pathies of immune-mediated, hypothyroid, dyslipidemic,
iatrogenic, and compressive origin.
Acupuncture has a history of over 3,000 years [10] and it
has been used for centuries in Asian countries to treat
different disorders, including pain syndromes, hemiplegia,
psychological illnesses, and obesity. In 1996, the Food
and Drug Administration approved acupuncture as a
medical device, and this technique has spread to treat
several conditions, such as low back pain, myofascial
pain, headache, sciatica, shoulder problems, tennis elbow
syndrome, migraine, and osteoarthritis of the knee [11]. In
China, the two most important indications for acupuncture
are Bell’s palsy and cerebrovascular accidents [12].
Among all these disorders, pain alleviation has been
accepted worldwide. The mechanism of acupuncture
analgesia, albeit poorly understood, has been attributed to
the modulation of endogenous opiates, growth factors,
gamma aminobutyric acid (GABA), and cytokines [13–17],
and influence of serotoninergic descending pain inhi-
bitory pathway [18]. However, the recent guidelines of the
Pain Medicine 2011; *: **–**
Wiley Periodicals, Inc.
1
American Society of Anesthesiologists Task Force and
American Society of Regional Anesthesia and Pain Medi-
cine recommended acupuncture as adjuvant to conven-
tional therapy only for nonspecific, noninflammatory low
back pain [19]. Acupuncture and electroacupuncture (EA)
are considered safe, although minor side effects have
been be reported, including bruising, mild discomfort,
and rarely fainting, nausea, and vomiting. The proce-
dure carries higher risk in patients with heart disease, neu-
tropenia, and compromised immunity, whereas EA is
contraindicated in patients with pacemaker [20].
There are two different strategies in performing acupunc-
ture therapy: manual and EA. The latter combines the
therapeutic effects of transcutaneous electric nerve
stimulation and manual acupuncture. EA is most used,
particularly for pain, because it can be standardized by
waveform, length, and frequency of stimulation. Indeed, it
has been suggested that different frequencies of stimu-
lation can modulate the release of different neuropep-
tides and pain mediators. Low-frequency (2–15 Hz) EA
engages centrally mediated endorphin, enkephalin, sero-
tonergic, and noradrenergic analgesia, and may engage
opioid-mediated immunomodulation [20]. High-frequency
(>100 Hz) EA engages segmental-spinal opioids (dynor-
phin, enkephalin) and non-opioid (GABA, glycine) analge-
sia [21]. Thus, low-frequency stimulation is most often
used for treating acute pain, whereas high-frequency
stimulation is most often used in chronic pain.
There is no conclusive evidence that acupuncture or EA is
effective in chronic neuropathic pain. The purpose of this
study was to assess, in a double-blind, cross-over study,
controlled vs placebo, the effectiveness of EA in reducing
the intensity of neuropathic pain in a selected group of
patients with painful neuropathy.
Patients and Methods
Patients aged 18–75 years with diagnosis of axonal
polyneuropathy based on clinical and neurophysiological
criteria, complaining of neuropathic pain at the lower
limbs inadequately controlled by pharmacological treat-
ment for at least 6 months, were considered. Inclusion
criteria were visual analog scale (VAS) score > 4, stable
analgesic intake for the last 3 months, and no condition
known to hinder the assessment of efficacy and toler-
ability. VAS score was obtained by asking the patients to
grade the mean severity of pain for the past 24 hours
using a 10-cm line with no anchors, on which the ends
indicate “no pain” and “worst possible pain.” Exclusion
criteria were history of alcohol or drug abuse, history
or presence of depression as assessed by the Beck
Depression Inventory scale (patients with score > 13
were excluded from the study), and any condition at
risk for EA (e.g., pacemaker). The study was approved
by the local ethics committee. Patients were included
after giving written informed consent. The study was per-
formed between September 2007 and September
2009.
Patients were randomly assigned to EA or pseudo-
electroacupuncture (pseudo-EA = placebo) as the starting
treatment. They remained blind as to the type of treatment
over the entire study period. To maintain the double-blind
conditions, the examiners (PP, GL) were not informed of
the type of treatment and assessed the efficacy and tol-
erability independently from the acupuncturists (MB, AS).
Each patient underwent six sessions of EA for 30 minutes
each at intervals of 5–7 days. EA was performed by deliv-
ering alternating current electrical stimuli (biphasic square
wave generated by a stimulator device specific acupunc-
ture) at low voltage (6 mV) and low frequency (2–10 Hz).
Current intensity was graded on the sensory response of
individual patients to a maximum of 70 mA. For analgesia
in the lower limbs, the acupoints were 36St Zusanli and
6 M Sanyinjiao, whereas for feet, they were 3F Taichong
and 60V Kunlun. Pseudo-EA was performed by applying
the needle in neutral anatomical points, close to the acu-
points, and delivering electrical stimulation with the same
pattern as previously described [22]. At the end of the six
sessions of EA or pseudo-EA, after a pause of 12 weeks,
patients who had undergone EA were treated with
pseudo-EA and vice versa. Both patients and examiners
were kept blind on the type of treatment also during this
second phase of the study.
The primary outcome was the number of patients treated
with EA achieving at least 50% of pain relief at the end of
each treatment compared with pain intensity at baseline.
Secondary outcomes were changes in patient’s global
impression of change (PGIC), depression and anxiety, and
quality of life assessed by the SF-36 questionnaire admin-
istered at baseline and at the end of therapy.
Pain intensity was assessed by the VAS for pain. The scale
was administered at the screening visit (baseline), at each
treatment session immediately before the application of
needles, at the end of the first and second treatment
cycles, and at 15 and 30 days after the last session to
assess the duration of analgesia. Adverse events and side
effects were recorded. All patients were asked to maintain
stable regimen of pretrial analgesics over the entire study.
Results
Sixteen subjects were included: nine female and seven
male, with mean age of 64.9 years (range 43–75). Neur-
opathy was associated with diabetes in four patients,
whereas it was idiopathic in 12 patients after screening for
diabetes, impaired glucose tolerance, vitamin deficiencies,
viral infections, systemic immune-mediated disorders, and
malignancies.
Only one patient per group (EA and pseudo-EA) achieved
50% of pain relief after treatment compared with pain
intensity at baseline. Pain intensity did not differ between
patients treated with EA (5.7  2.3 at baseline and
4.97  3.23 after treatment) and those treated with
pseudo-EA (4.9  1.9 at baseline and 4.18  2.69 after
treatment). There was also no difference when we ana-
lyzed separately patients who received EA as the first
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treatment and patients initially treated with pseudo-EA.
There was no change in pain intensity comparing baseline
and study end values when we pooled all the treatments
(EA and pseudo-EA) as one group (5.0  3.0 at baseline
and 5.4  2.2 at study end). PGIC did not significantly
change compared with baseline, even when EA was
administered as first or second treatment. Finally, there
was no significant change in anxiety, depression, and
quality of life and sleep before and after treatments.
Treatment was well tolerated and no side effect was
recorded. Alternating current electrical stimulation was
never referred to as unpleasant or painful. All patients
maintained stable drug intake during the entire study
period.
Discussion
Alternative medicine has become increasingly attractive in
the Western world among physicians and patients suffer-
ing from different diseases. In particular, acupuncture is
the most common approach in patients with chronic
pain [23,24]. However, classical anatomy and physiology
cannot be applied to the concepts of Chinese medicine on
which the methodological bases of acupuncture are
based. The mechanism of action of acupuncture analge-
sia has been extensively explored for the last 40 years.
Different hypotheses have been proposed, but a unifying
consensus has not been achieved. Until the 1990s, one of
the most reliable theories, based on studies in animal
models, claimed that low-frequency EA can stimulate the
release of beta-endorphin, enkephalin, and endomorphin
that activate d- and m-opioid receptors and of dinorphin
that activates k-opioid receptors [14,25–28]. The sero-
toninergic descending inhibitory pathway has also been
suggested to be relevant to acupuncture analgesia. In
particular, the injection of serotonin synthesis inhibitor or of
5-HT1/3 antagonists can decrease the analgesic effect of
2-Hz EA at both low and high frequencies (2 and 100 Hz),
whereas EA analgesia is enhanced by 5-HT2 antagonists
at high frequencies (100 Hz) [18,29–31]. Moreover, sero-
tonin levels are increased in the spinal cord during EA [29].
Data on the effectiveness of acupuncture in controlled
clinical trials are controversial. An extensive review of avail-
able clinical trials until 1990 by ter Riet et al. concluded
that the effectiveness of acupuncture in the treatment of
pain remained doubtful and the results are highly con-
tradictory [32]. In 1997, a committee of the American
National Institutes of Health concluded that there was
sufficient evidence for acupuncture as a treatment for
pain. The committee was strongly criticized, arguing that it
was composed mainly of supporters of medical acupunc-
ture and that reviews in the field tended to be written by
enthusiasts often with the underlying assumption that it is
a valuable therapy [33]. In 2000, a review of 51 clinical
trials for a total of 2,423 patients with chronic pain con-
firmed the previous negative conclusions [34]. According
to the authors, there was limited evidence that acupunc-
ture can provide pain relief compared with patients who
did not receive any treatment. A further review by Birch
et al. [35] stated that acupuncture appears to be effective
for postoperative dental pain, postoperative nausea and
vomiting, and chemotherapy-related nausea and vomit-
ing. In 2009, a meta-analysis of 13 studies on different
types of pain in 3,025 patients [36] showed a minimal
efficacy of EA when compared with pseudo-EA and
untreated patients, but the effect was variable and cannot
be distinguished from bias resulting from incomplete
blinding. Moreover, the effect of placebo did not seem to
be related to the method used, such as insertion of
needles in non-acupuncture points or non-penetrating
needles. Conversely, a recent study in patients with dia-
betic neuropathy reported a positive effect on numbness,
spontaneous pain, rigidity, and altered temperature per-
ception compared with placebo [37]. In a 10-week uncon-
trolled study on 46 patients with diabetic neuropathy,
acupuncture induced pain relief in 77% of them and
symptom resolution in 21% [38]. In another study, Walker
[39] reported the efficacy of acupuncture performed once
a week for 2–3 months in 90% of 40 patients in terms of
pain, sleep, mobility, and mood improvement. The authors
also reported a long-term effect, suggesting that a single
cycle of treatment could be usually sufficient to reduce
recurrent symptoms.
However, the number of randomized controlled clinical
trials in homogeneous groups of patients with painful neu-
ropathy is very limited. Two small studies on 11 and 23
patients showed pain relief [40,41], but in a larger random-
ized, placebo-controlled, multicenter clinical trial on 250
patients with HIV-associated painful neuropathy, acu-
puncture was not significantly more effective than placebo
[42].
Our study did not show any of the efficacy of EA on
neuropathic pain, sleep, and quality of life in a homoge-
neous group of patients with painful neuropathy. Although
its major limitation is the small population of patients, the
cross-over design used to undergo each patient blindly to
both sham and true EA eliminated the bias of placebo
effect. However, it has been suggested that placebo acu-
puncture is not suitable for comparison in randomized
clinical trials because it is not completely inert [43]. In
our study, this does not seem a relevant issue as neither
EA nor pseudo-EA on neutral points allowed achieving
significant pain relief. In conclusion, our results do not
support the use of EA as analgesic treatment in patients
with chronic painful neuropathy.
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